Västra Hamnen: ViroGates - Detects COVID-19 relevance

Västra Hamnen Corporate Finance has published a research update on ViroGates following its Quarterly Report for Q1 2020. The numbers were largely in line with expectations. The bigger news is an early indication that suPAR can be helpful in triaging COVID-19 patients, writes Västra Hamnen.
 

  • suPAR determines severity of COVID-19 in preliminary study
  • Steady increase in hospitals evaluating suPARnostic® for clinical use
  • We keep our valuation interval unchanged

ViroGates published its quarterly report for Q1 2020 last week. The figures showed somewhat lower revenues, but even lower costs compared with our expectations, yielding a net profit slightly better than our estimates. The report was however overshadowed by the news last Thursday that ViroGates’ suPAR test has shown to be relevant in triaging COVID-19 patients. Clinical results show that suPAR has significant predictive power in identifying which patients are likely to develop severe respiratory failure (SRF). This is highly interesting with respect to future sales of ViroGates’ products.

The full report is available here.

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se

Om os

ViroGates is an international Medtech company headquartered in Denmark, north of Copenhagen, in the heart of Medicon Valley. ViroGates was founded in 2001, based on an invention coming from Hvidovre Hospital, Denmark. Inventor and co-founder Jesper Eugen-Olsen discovered the utility of the biomarker suPAR in HIV. More than 600 publications have followed, substantiating suPAR as one of the most promising biomarker tools for various areas of healthcare. ViroGates has developed a product line called suPARnostic® to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision making.

Abonner